Henke 2003.

Methods	randomized controlled trial, placebo‐controlled
Participants	n = 351, head and neck cancer (advanced, stage III, IV); concomitant treatment: radiotherapy
Interventions	drug = Epoetin beta dose = 300 IU/kg sc TIW hb‐target = 12‐14 g/dL (women), 13‐15 g/dL (men) planned ESA duration = during radiotherapy
Outcomes	Primary: efficacy of radiotherapy, measured as local progression free survival; secondary: survival, progression free survival, Hb, safety, tolerability
Notes	study number = 58106
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	Each center had numbered packages per stratum, once randomized the lowest number had to be assigned. There was a randomization list only the statistics center had access to. In addition, there were sealed envelopes for emergencies.
Allocation concealment?	Low risk	coded drug packs of identical appearance